Cirius Therapeutics Completes Enrollment in Phase 2b EMMINENCE Trial in NASH

Having recently completed a series A financing round of up to $40 million, Cirius Therapeutics announced on 5/2/2018 that it has reached its enrollment target in its Phase 2b EMMINENCE trial for its lead program MSDC-0602K in more than 380 patients with NASH and liver fibrosis. The study is using liver biopsy at 12 months to measure changes in liver tissue, including resolution of NASH, reduction of fibrosis and changes in NAFLD activity score, for its primary and secondary endpoints.